Alterations of the p16-pRb Pathway and the Chromosome Locus 9p21-22 in Non-Small-Cell Lung Carcinomas Relationship with p53 and MDM2 Protein Expression

作者: Vassilis G. Gorgoulis , Panayotis Zacharatos , Athanassios Kotsinas , Triantofillos Liloglou , Aspasia Kyroudi

DOI: 10.1016/S0002-9440(10)65690-8

关键词:

摘要: The p16-pRb and p53-MDM2 pathways represent vital cell cycle checkpoints. Recent studies provide evidence that these are directly linked via MDM2-pRb interaction p53 suppression of the RB1 gene. In present study we investigated alterations this G1 phase protein network using immunohistochemical molecular methods in a series 68 non-small-cell lung carcinomas (NSCLCs) correlated findings with clinicopathological features prognosis patients. Aberrant expression (Ab) p16 pRb was observed 33 (49%) 27 (40%) carcinomas, respectively. Analysis region encodes for by deletion mapping, polymerase chain reaction (PCR)-based methylation assay PCR single-strand conformation polymorphism (SSCP) analysis revealed deletions transcriptional silencing might main mechanisms CDKN2/p16ink4a inactivation NSCLCs. results mapping also suggest other tumor suppressor genes may reside at 9p21-22 region, which CDKN2/MTS1/p16ink4a, p14ARF, MTS2/p15ink4b. addition, microsatellite instability frequency 16% chromosome area. Overexpression (P) MDM2 proteins found 39 (58%) 47 (70%) cases, A highly significant association between overexpression mutations (P = 0.006). Statistical patterns biologically relevant molecules (p16/pRb, p53/MDM2, MDM2/pRb, p53/pRb) showed coincident 0.04) abnormal elevated levels 0.013) 0.01), We deregulated act synergistically. An important finding multiple impairments (three four affected) p16/pRb/p53/MDM2 occurred large proportion (43%) carcinomas. This addition to absence correlation clinical stage tumors suggests hits be relatively early event development subset relationship factors examined study, features, survival patients did not reveal any correlations exception smoking, associated (loss heterozygosity instability) locus immunophenotypes p53(P)/MDM2(P) p16(Ab)/pRb(Ab)/p53(P)/MDM2(P) 0.03), NSCLCs, simultaneous deregulation members one way initiating oncogenic procedure whereas NSCLC subgroups alternative play role.

参考文章(89)
Gary Clayman, Mario A. Luna, Helmuth Goepfert, Syeling Lai, Adel K El-Naggar, Jiun-Kae Jack Lee, John G. Batsakis, Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. American Journal of Pathology. ,vol. 151, pp. 1767- 1774 ,(1997)
Piantadosi S, Figlin Ra, Holmes Ec, Koga H, Reissmann Pt, Takahashi R, Slamon Dj, Cordon-Cardo C, Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer Oncogene. ,vol. 8, pp. 1913- 1919 ,(1993)
M. M. Bertholet, F. Bosman, L. Guillou, A. M. Kurt, H. J. Leisinger, G. Metthez, P. Shaw, P. Chaubert, Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors. American Journal of Pathology. ,vol. 151, pp. 859- 865 ,(1997)
S. N. Khleif, F. J. Kaye, Weidong Chen, A. B. Coxon, G. A. Otterson, CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine. Oncogene. ,vol. 11, pp. 1211- 1216 ,(1995)
R. A. Kratzke, F. J. Kaye, Young Whan Kim, A. Coxon, G. A. Otterson, Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene. ,vol. 9, pp. 3375- 3378 ,(1994)
A Hangaishi, S Ogawa, N Imamura, S Miyawaki, Y Miura, N Uike, C Shimazaki, N Emi, K Takeyama, S Hirosawa, N Kamada, Y Kobayashi, Y Takemoto, T Kitani, K Toyama, S Ohtake, Y Yazaki, R Ueda, H Hirai, Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies Blood. ,vol. 87, pp. 4949- 4958 ,(1996) , 10.1182/BLOOD.V87.12.4949.BLOODJOURNAL87124949
Hiromitsu Hiroumi, Hirotoshi Dosaka-Akita, Takayuki Mishina, Ichiro Kinoshita, Fumihiro Hommura, Yoshikazu Kawakami, Kenji Akie, Motoi Nishi, Altered p16INK4 and Retinoblastoma Protein Status in Non-Small Cell Lung Cancer: Potential Synergistic Effect with Altered p53 Protein on Proliferative Activity Cancer Research. ,vol. 56, pp. 5557- 5562 ,(1996)
C Cordon-Cardo, Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. American Journal of Pathology. ,vol. 147, pp. 545- 560 ,(1995)
Hong Ji Xu, William F. Benedict, George E. Moore, Shi Xue Hu, Philip T. Cagle, Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Research. ,vol. 51, pp. 2735- 2739 ,(1991)